Cuban scientists said today the first vaccine to extend lives of lung cancer patients has been approved by Cuban authorities for use and is available in the island's hospitals.
The drug, CimaVax EGF, has been shown to increase survival rates on average four to five months and much longer in some patients, they said in a news conference at Cuba's Center of Molecular Immunology.
In contrast to chemotherapy, the traditional treatment for lung cancer, they said CimaVax EGF has few side effects because it is a modified protein that attacks only cancer cells.
They said it was the first lung cancer vaccine to be approved anywhere in the world, although there are others currently being tested.
"It's the first vaccine for lung cancer registered in the world," said Gisela Gonzalez, who headed the development of the vaccine, begun in 1992.
The drug is in various stages of clinical trials in a number of other countries and is most likely to be approved next in Peru, where it could be publicly available by year's end, Ms Gonzalez said.
The drug has been approved for clinical trial in the United States, but its possible use there is at least two to three years away, she added.
Ms Gonzalez said several private companies had been licensed to market the vaccine, but it will be produced in Cuba. Cost for the treatment had not yet been determined, she added.
Havana's molecular immunology centre said people from outside Cuba can come to the island for treatment.